Dr. Parone is an accomplished scientific innovator and proven leader in the biotechnology industry, with over 25 years of experience spanning both academia and the private sector. He holds a Ph.D. in Biochemistry from the University of Cambridge, with a strong foundation in molecular neuroscience and a focus on translational research.

He began his career as a postdoctoral fellow at the University of Geneva, later transitioning to the Ludwig Institute for Cancer Research at the University of California, San Diego. He then joined Fate Therapeutics, where he held roles of increasing responsibility. During his time at Fate Therapeutics, Philippe led the development of iPSC and patient derived immuno-regulatory cell therapies for the treatment of immune disorders, including T1D, MS and GvHD and he oversaw companywide IND enabling safety pharmacology studies for iPSC derived cell therapy products for the treatment of hematological malignancies.

Prior to his role at EsoBiotec, Philippe was Director of Industrialization at Celyad Oncology where he was pivotal in directing manufacturing programs and advancing both autologous and allogeneic cell therapies into first in human studies.

Currently serving as Chief Scientific Officer at EsoBiotec, Philippe directs scientific strategy and leads R&D efforts with a focus on developing advanced therapies for cancer and immune disorders. Philippe's leadership drives cutting-edge advancements in cell and gene therapy, positioning EsoBiotec at the forefront of the biotech industry.